Valuation: electroCore, Inc.

Market Cap 50.48M 43.88M 40.84M 37.5M 70.82M 4.82B 71.91M 481M 189M 2.4B 190M 185M 8.04B P/E 2026 *
-4.1x
P/E 2027 * -14x
Enterprise Value 48.88M 42.49M 39.55M 36.31M 68.57M 4.67B 69.63M 466M 183M 2.32B 184M 180M 7.79B EV / Sales 2026 *
1.17x
EV / Sales 2027 * 0.77x
Free-Float
67.6%
Yield 2026 *
-
Yield 2027 * -
1 day+4.90%
1 week+1.90%
1 month-24.11%
3 months+1.90%
6 months-1.83%
Current year+40.05%
1 week 5.1
Extreme 5.1
5.35
1 month 4.82
Extreme 4.82
7.45
Current year 3.58
Extreme 3.58
9.1
1 year 3.48
Extreme 3.48
9.1
3 years 3.48
Extreme 3.48
9.1
5 years 2.5
Extreme 2.5035
16.2
10 years 2.5
Extreme 2.5035
181.65
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 63 01/05/2017
Director of Finance/CFO 41 01/10/2024
Chief Operating Officer - 13/04/2026
Director TitleAgeSince
Chairman 74 02/09/2025
Director/Board Member 65 02/04/2020
Director/Board Member 64 15/03/2022
Change 5-day change 1-year change 3-year change Capi.($)
+4.90%+1.90% - - 50.48M
+0.43%+0.77%+32.17%+19.20% 12.65B
+0.55%+3.08%+25.28%+21.62% 6.78B
-1.75%-0.54%+49.54%+24.87% 5.98B
-0.52%+7.25% - - 5.07B
+3.47%+9.59%-18.67%+46.80% 4.75B
+0.32%+5.56%-19.89%-16.58% 4.15B
+0.32%+5.10%-25.54%+213.39% 1.84B
-2.56%-15.92%+31.10%-50.68% 1.73B
+0.16%-4.85%+56.70%-8.43% 1.58B
Average +0.53%+2.09%+16.34%+31.27% 4.95B
Weighted average by Cap. +0.24%+3.26%+20.28%+24.90%

Financials

2026 *2027 *
Net sales 41.92M 36.44M 33.92M 31.14M 58.81M 4B 59.72M 400M 157M 1.99B 157M 154M 6.68B 54.23M 47.14M 43.88M 40.29M 76.08M 5.18B 77.25M 517M 203M 2.58B 204M 199M 8.64B
Net income -13.49M -11.73M -10.91M -10.02M -18.92M -1.29B -19.22M -129M -50.49M -641M -50.66M -49.54M -2.15B -4.46M -3.88M -3.61M -3.31M -6.25M -426M -6.35M -42.52M -16.69M -212M -16.74M -16.37M -710M
Net Debt -1.6M -1.39M -1.29M -1.19M -2.24M -153M -2.28M -15.26M -5.99M -76.04M -6.01M -5.88M -255M -8.5M -7.39M -6.88M -6.31M -11.92M -811M -12.11M -81.07M -31.82M -404M -31.92M -31.22M -1.35B
Logo electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Employees
83
Date Price Change
31/07/26 €5.350 +4.90%
30/07/26 €5.100 -.--%
29/07/26 €5.100 -.--%
28/07/26 €5.100 -1.92%
27/07/26 €5.200 -0.95%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.085USD
Average target price
19.57USD
Spread / Average Target
+221.61%

Quarterly revenue - Rate of surprise